Govt says PLI schemes for bulk drugs, medical devices get encouraging response

Published On 2020-11-28 06:55 GMT   |   Update On 2021-11-23 11:50 GMT

New Delhi: Production Linked Incentive (PLI) schemes for Bulk Drugs and Medical Devices have received a very encouraging response from the industry, Ministry of Chemicals and Fertilizers said on Friday. The PLI scheme for Bulk Drugs has received 247 registrations across all four categories of products out of which a maximum of 136 applicants will be selected under the scheme, it added.The...

Login or Register to read the full article

New Delhi: Production Linked Incentive (PLI) schemes for Bulk Drugs and Medical Devices have received a very encouraging response from the industry, Ministry of Chemicals and Fertilizers said on Friday.

The PLI scheme for Bulk Drugs has received 247 registrations across all four categories of products out of which a maximum of 136 applicants will be selected under the scheme, it added.

The PLI scheme for Medical Devices has received 28 registrations across all four target segments out of which a maximum of 28 applicants will be selected under the scheme, the ministry said. The last date for filing the application under both the schemes is November 30, 2020.

Read also: Govt extending production linked incentives for upcoming bulk drug, medical device parks manufacturing units: Gowda

Production Linked Incentive schemes for Bulk Drugs and for Medical Devices were approved by the government on March 3, 2020, and the revised guidelines for implementation of both the schemes were issued on October 29, 2020.

Read also: Department of Pharmaceuticals revises PLI scheme guidelines to promote domestic production of bulk drugs, medical devices



Tags:    
Article Source : PTI

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News